ANEBULO PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 254.43K shares.
- ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 982.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares 10-Q · filed 2026-02-12 | 0.00 shares 10-Q · filed 2026-02-12 | |||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-13 | ||||
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | 254.43K shares derived: sum of 2 quarters · filed 2026-02-12 | 254.43K shares derived: sum of 3 quarters · filed 2026-02-12 | ||
| 2024-12-31 | 254.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | 254.43K shares 10-Q · filed 2026-02-12 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-13 | ||||
| 2021-06-30 | 378.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | 982.50K shares 10-K · filed 2022-09-09 | 604.40K shares 10-K · filed 2021-09-22 | ||
| 2021-03-31 | 604.40K shares 10-Q · filed 2021-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |